Select your timezone:

Optimizing Differentiation to Stem Cell Beta Cells

Monday April 24, 2023 - 10:00 to 11:15

Room: Riverfront


.1 Human pluripotent stem cell-derived pancreatic beta cells for disease modeling


Dr. Shuibing Chen is the Kilts Family Professor, Vice Chair of Innovation, and the Director of the Diabetes Program in the Department of Surgery, and the Director of the Center of Genomic Health at Weill Cornell Medicine. She received my B.S. and M.S. in Chemistry from Tsinghua University in China. Then, she pursued my PhD under the advisement of Dr. Peter G. Schultz at the Scripps Research Institute. After graduation, she joined Dr. Doug Melton’s laboratory at Harvard University. The major research interest in the Chen Laboratory focuses on human pluripotent stem cell-derived organoids for disease modeling and drug screening. In response to the COVID-19 pandemic, Dr. Chen created a panel of human pluripotent stem cell-derived cells/organoids to study SARS-CoV-2 infection. Part of these work has been published on Nature, Cell Stem Cells, Cell Metabolism, Circulation Research, etc. Dr. Chen serves on the editorial board of Cell Stem Cell, Stem Cell Reports, Journal of Molecular Cell Biology, et al. She also serves as the Chair of the Scientific Program Committee of International Chemical Biology Society. She has received many awards including New York Stem Cell Foundation Robertson Investigator, American Diabetes Association (ADA) Innovative Award, NIH Director’s New Innovator Award, and ISSCR Dr. Susan Lim Award for Outstanding Young Investigator, etc.

Organized by

A section of

© 2024 BetaCells 2023